MBX Biosciences to Release Promising Data on Once-Weekly Hypoparathyroidism Treatment
carmel, IN – September 19, 2025 – MBX Biosciences, Inc. (Nasdaq: MBX), a leader in precision peptide therapies, announced today it will release topline results from its Phase 2 clinical trial evaluating canvuparatide, a potential once-weekly treatment for chronic hypoparathyroidism (HP). The data will be presented during an investor webcast on Monday, September 22nd.
Hypoparathyroidism is a rare endocrine disorder where the body doesn’t produce enough parathyroid hormone, leading to low calcium levels. current treatments often require daily injections or multiple doses of calcium and vitamin D, presenting a important burden for patients. Canvuparatide aims to address this unmet need with a convenient, once-weekly administration.
The Phase 2 “Avail™” trial data is highly anticipated by the medical community and investors alike. MBX Biosciences is developing canvuparatide using its proprietary PEP™ platform, focusing on precision peptide therapies for endocrine and metabolic disorders.
Webcast Details:
* date: Monday, September 22, 2025
* time: 8:00 AM ET
* Webcast Link: https://www.globenewswire.com/Tracker?data=3OCxm56okgZn09U-znSV3zBrEfDl0D7nR3YJ271nEpqEgWf30pXudVBT0fQQQN2kSMHh6f9IJoK5VUU8bJyZqX4OnCPyUvyBoTKOvoFl5By9KT_jy0Am-IEIJlVwq-0KxSIY1b7Y2Hog5AiIinrIGw==
* Dial-in: 1-877-407-0779 (US) or 1-201-389-0914 (International)
The presentation and archived webcast will also be available on the MBX Biosciences investor relations website: https://investors.mbxbio.com/news-events/events
About MBX Biosciences:
MBX Biosciences is a clinical-stage biopharmaceutical company dedicated to developing innovative peptide therapies for endocrine and metabolic disorders. The company’s pipeline targets conditions with significant unmet medical needs and ample market potential.
Further Information:
* MBX Biosciences Website: https://mbxbio.com/
* MBX Biosciences LinkedIn: https://www.globenewswire.com/Tracker?data=6hWEPLbortEyE7ffDy6FrnxgfDfzSjOl2gtPofE941E7jaEk5A33AktTzFY3GdoHuo03iNlHHX9flWw8_DiqTzBdeR2YtUuEeG_m8QOSuhlbbBaVV_sl-cMUAtG-jW5X
Media Contact:
Katie Beach Oltsik
